400 The underlying neuroprotective mechanisms involve increased levels of miR-21, miR-27a, and miR-146a, along with decreased expression of target proteins
October 22 Product : Camurus CAM2029 Indication : Acromegaly Manufacturing problems tripped up Camurus application for CAM2029, an investigational subcutaneous formulation of octreotide the Swedish company is developing acromegaly
A Photographic Field Guide to the Lizards of Thailand is out now
9.3 Bayesian and ML-driven DTRs: optimizing initiation, duration, and cessation In fertility management, the pivotal questions regarding GLP-1RAs are often not about efficacy in isolation, but rather the optimal timing of initiation, treatment duration, cessation, and sequencing with OI/ARTclassic Dynamic Treatment Regime (DTR) problems
Tirzepatide, without glucagon agonism, does not carry that specific signal
According to NICE guidance (TA494), treatment should be discontinued if patients have not lost at least 5% of their initial body weight after 16 weeks
